ELV — Elevance Health, Inc.
Is ELV overbought or oversold? Here is the current MarketMoodz read.
Elevance Health, Inc. (ELV) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $433.93. The rating moved from Neutral to Overbought on November 16, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$433.93
- Last changeMoved from Neutral to Overbought on November 16, 2026
- SectorHealthcare
- IndustryHealthcare Plans
See all overbought Healthcare stocks →
AI analysis
Elevance Health, Inc. (ELV) benefits from scale in Medicare Advantage, Medicaid and commercial lines, strong cash generation and disciplined cost management that support near-term revenue and margin stability. Recent CMS proposals raise regulatory and program-integrity risk that could create episodic earnings volatility or increased compliance costs, but defensive flows into large-cap healthcare and ongoing MA enrollment growth provide offsetting support. Key near-term drivers include RADV rule development, enrollment trends, medical-loss ratio management, and execution on provider cost controls; outcomes will shape upside versus downside scenarios over the coming month.
Key factors
- Large, diversified market position across Medicare Advantage, Medicaid, and commercial lines with scale advantages in provider networks and claims analytics
- Medicare Advantage enrollment growth and favorable demographic tailwinds supporting membership and premium leverage
- Strong free cash flow and capital deployment flexibility to support buybacks/dividends and strategic M&A
- Defensive sector flows into large-cap healthcare insurers amid market consolidation and risk-averse positioning
- Proven medical cost management and underwriting discipline that supports margin resilience versus peers
- Limited near-term volatility in broader markets allowing fundamentals and earnings to drive relative performance
Risks
- CMS proposed RADV / anti-fraud measures increasing near-term regulatory uncertainty and potential clawbacks of MA overpayments
- Aggressive $0-premium & benefit expansion by competitors could pressure pricing dynamics and benefit cushions, compressing margins
- Healthcare cost inflation or unexpected utilization spikes (e.g., infectious disease waves) that widen medical-loss ratios
- Intensifying competition from other large insurers (UnitedHealth, CVS Health) and risk-bearing entities on MA and specialty products
- Execution risk around maintaining network economics and care management effectiveness as enrollment grows
- Policy or legal actions (state/federal) altering reimbursement, prior authorization rules, or provider contracting dynamics
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ELV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.